NCT03050086已完成1 期
An Open Label Phase 2 Feasibility Study to Assess the Safety and Efficacy of BPX-04 Minocycline Topical Gel in Treatment of Moderate to Severe Papulopustular Rosacea (BPX-01-C05)
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Investigator's Global Assessment
研究概览
简要总结
An open label feasibility study using BPX-04 topical minocycline gel in papulopustular rosacea.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female subjects ≥18 years of age at the time of consent.
- •Subjects do not have any medical conditions, other than rosacea, that in the opinion of the investigator, put the subject at unacceptable risk or could interfere with study assessments or integrity of the data.
- •A clinical diagnosis of moderate to severe (Grade 3 or 4) facial rosacea (papulopustular (Subtype 2) or mixed erythematotelangiectatic (Subtype 1) and papulopustular (Subtype 2)) as determined by the Investigator's Global Assessment (IGA) at Visit 1/Screening.
- •Female subjects of childbearing potential (including pre-puberty) are willing to use effective contraceptive method for at least 28 days before baseline (Day 0) and at least 28 days after the last study product administration or have a sterilized or same-sex partner for the duration of the study. Hormonal contraceptives must be on a stable dose for at least 12 weeks before baseline (Day 0). Subjects using low dose oral contraceptives must use a second form of birth control (e.g., barrier method such as condoms with spermicide).
- •Note: Female subjects of non-childbearing potential are defined as follows:
- •Female subjects who have had surgical sterilization (hysterectomy, bilateral oophorectomy, bilateral salpingectomy, or bilateral tubal ligation);
- •Female subjects who have had a cessation of menses for at least 12 months and a follicle-stimulating hormone (FSH) test confirming non-childbearing potential (refer to the central laboratory reference range for menopausal women) or cessation of menses for at least 24 months without FSH levels confirmed;
- •Female subjects of childbearing potential must have a negative urine pregnancy test at screening and baseline (Day 0).
- •Treatment with hormonal therapy must be on a stable dose and frequency for at least 12 weeks before baseline (Day 0) and must remain stable throughout the study.
- •Subjects who use make-up, facial moisturizers, creams, lotions, cleansers and/or sunscreens must have used the same product brands/types for a minimum period of 14 days prior to baseline (Day 0), must agree not to change brand/type or frequency of use throughout the study and must agree not to use make-up, facial moisturizers, creams, lotions, cleansers and/or sunscreens on the clinic visit days before the visit.
- •Subjects must be capable of giving informed consent and the written informed consent must be obtained prior to any study-related procedures.
排除标准
- •Have a history of skin disease, presence of skin condition or excessive facial hair the PI believes would interfere with the study
- •Have moderate or severe rhinophyma, severe telangiectasia or plaque-like facial edema
- •Have rosacea conglobata or fulminans, corticosteroid induced rosacea or facial erythrosis other than rosacea
- •Have ocular rosacea of a severity that requires systemic treatment
- •Have a history of any adverse reaction to minocycline or other tetracycline class antibiotic
- •Have a clinically significant chemistry or hematology value at baseline or have an ALT or AST at screening that is greater than or equal to 2x normal
- •Have conditions or factors that the PI believes may affect the response of the skin or the interpretation of the results
- •Participated in any clinical study with exposure to any investigational treatment or product within the previous 30 days, or plan on concurrent participation in other studies
- •Have used on the face an OTC topical medication for the treatment of rosacea within 4 weeks prior to baseline.
- •Have used prescription topical (on the face) or oral antibiotics or corticosteroids within 4 weeks prior to baseline.
- •Have had a facial procedure such as chemical peel, laser, microdermabrasion within 8 weeks prior to baseline
- •Have received photodynamic therapy or phototherapy with blue or red light within 12 weeks prior to baseline
- •Have used an oral retinoid within 6 months or a topical retinoid within 3 months prior to baseline
- •Current drug or alcohol abuse
- •Female subject who is breastfeeding, pregnant or who is planning a pregnancy during the study.
研究组 & 干预措施
BPX-04 1% Minocycline Topical Gel
Experimental
once daily topical administration of 1% minocycline gel to the face
干预措施: BPX-04 1% minocycline topical gel (Drug)
BPX-04 2% Minocycline Topical Gel
Experimental
once daily topical administration of 2% minocycline gel to the face
干预措施: BPX-04 2% minocycline topical gel (Drug)
BPX-01 Vehicle Topical Gel
Placebo Comparator
once daily topical administration of vehicle gel to the face
干预措施: BPX-04 vehicle topical gel (Drug)
结局指标
主要结局
Investigator's Global Assessment
时间窗: 12 weeks
papules, pustules and erythema
次要结局
- Lesion count(12 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Topical Ruxolitinib for the Treatment of VitiligoVitiligoNCT02809976Tufts Medical Center11
已完成
2 期
Open Label, Safety and Efficacy Study of Topical Investigational Drug to Treat Patients With PsoriasisPsoriasisNCT00617994Incyte Corporation25
已完成
2 期
A Study of ELX-02 in Patients With Alport SyndromeAlport SyndromeNCT05448755Eloxx Pharmaceuticals, Inc.3
已完成
2 期
Open Label Study of Subcutaneous Homoharringtonine (Omacetaxine Mepesuccinate) in Patients With Advanced CMLChronic Myeloid LeukemiaNCT00462943Teva Branded Pharmaceutical Products R&D, Inc.100
已完成
不适用
Clinical Investigation on the Safety and Clinical Performance of Papix Acne Scar.ScarsAcneNCT04806594Relife S.r.l.40